Samalin, Ludovic
Vieta, Eduard
Okasha, Tarek Ahmed
Uddin, MM. Jalal
Ahmadi Abhari, Seyed Ali
Nacef, Fethi
Mishyiev, Vyacheslav
Aizenberg, Dovi
Ratner, Yaƫl
Melas-Melt, Lydie
Sedeki, Idir
Llorca, Pierre Michel
Article History
Received: 14 March 2016
Accepted: 25 April 2016
First Online: 16 May 2016
Competing interests
: Dr Samalin received grants, honoraria, or consulting fees from AstraZeneca, Bristol-Myers Squibb, Janssen-Cilag, Lundbeck, Otsuka, Sanofi, and Takeda. Pr Vieta received grants, CMErelated honoraria, or consulting fees from Alexza, Almirall, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Ferrer, Forest Research Institute, Gedeon Richter, GlaxoSmithKline, Janssen, Janssen-Cilag, Jazz, Johnson & Johnson, Lundbeck, Merck, Novartis, Organon, Otsuka, Pfizer, Pierre-Fabre, Qualigen, Roche, Sanofi, Schering-Plough, Servier, Shire, Solvay, Takeda, Teva, CIBERSAM, the Seventh European FrameWork Programme (ENBREC), the Stanley Medical Research Institute, United Bio-source Corporation, and Wyeth. Pr Okasha received honoraria from Sanofi. Dr Jalal Uddin received honoraria from Sanofi. Dr Ahmadi Abhari received grants, honoraria, or consulting fees from Pfizer, Actover, Bayer, Sanofi and Shafayab Pr Nacef received honoraria for consulting and lecturers from Sanofi Pr Mishyiev received honoraria for consulting and lecturers from Sanofi, Lundbeck and Janssen. Pr Aizenberg received honoraria from Sanofi. Dr Ratner received honoraria from Sanofi. Pr Llorca received grants, honoraria, or consulting fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Ferrer, Janssen-Cilag, Lundbeck, Otsuka, Sanofi, Servier, and Takeda.